Cost per median month of progression-free survival for daratumumab plus bortezomib and dexamethasone compared with carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma.

被引：0
|
作者：
Maiese, Eric
Graham, Christopher N.
Hawe, Emma
Le Moine, Jean-Gabriel
机构：
[1] Janssen Sci Affairs, LLC, Horsham, PA USA
[2] RTI Hlth Solut, Res Triangle Pk, NC USA
[3] RTI Hlth Solut, Manchester, Lancs, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e20037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20037
引用
收藏
页数：2
相关论文
共 50 条
  • [11] EFFICACY AND SAFETY OF BORTEZOMIB PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Sanchez, R. Garcia
    Saldana, R.
    Caparros, I.
    Gallardo, A.
    Garcia-Delgado, R.
    Rosell, A.
    Campos, A.
    de Llano, M. P. Queipo
    Perez, I.
    Moreno, M. J.
    Del Castillo, S.
    De la Torre, S.
    Ramirez, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 500 - 500
  • [12] Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data
    Li, Shuo
    Meng, Xiang-Yu
    Maman, Souraka Tapara Dramani
    Xiao, Yong-Nong
    Li, Sheng
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [13] Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
    Richter, Joshua
    Lin, Peggy L.
    Garcia-Horton, Viviana
    Guyot, Patricia
    Singh, Erin
    Zhou, Zheng-Yi
    Sievert, Mark
    Taiji, Riley
    CANCER MEDICINE, 2023, 12 (07): : 8005 - 8017
  • [14] A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew J.
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Bianchi, Giada
    O'Donnell, Elizabeth
    Branagan, Andrew R.
    Harrington, Cynthia C.
    Agyemang, Emerentia A.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Packer, Lisette A.
    Bernstein, Zachary S.
    Lyons, Rebecca T.
    Riadi, Manal
    Rowell, Sean M.
    Mcvey, Cailin
    Goguen, Amy C.
    Horick, Nora K.
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [15] Weekly Carfilzomib Combined with Daratumumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
    Xu, Jiadai
    Liu, Peng
    BLOOD, 2024, 144 : 7052 - 7053
  • [16] Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, plus /- bortezomib, in patients with relapsed/refractory multiple myeloma.
    Kaufman, Jonathan L.
    Baz, Rachid C.
    Harrison, Simon J.
    Quach, Hang
    Ho, Shir-Jing
    Vangsted, Annette J.
    Moreau, Philippe
    Gibbs, Simon D. J.
    Salem, Ahmed H.
    Coppola, Sheryl
    Ross, Jeremy A.
    Masud, Abdullah A.
    Westrup, Sally
    Vue, Jenny
    Maciag, Paulo Cesar
    Bueno, Orlando
    Bahlis, Nizar J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [17] A matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone versus daratumumab plus lenalidomide and dexamethasone for relapsed multiple myeloma
    Richter, Joshua
    Lin, Peggy
    Garcia-Horton, Viviana
    Guyot, Patricia
    Singh, Erin
    Zhou, Zheng-Yi
    Sievert, Mark
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S156 - S157
  • [18] Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma
    Weber, Donna
    Knight, Robert
    Chen, Christine
    Spencer, Andrew
    Yu, Zhinuan
    Zeldis, Jerome
    Olesnyckyj, Marta
    Dimopoulos, Meletios
    BLOOD, 2007, 110 (11) : 128A - 128A
  • [19] Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
    Cerchione, Claudio
    Nappi, Davide
    Cangini, Delia
    Ronconi, Sonia
    Ceccolini, Michela
    Musuraca, Gerardo
    Martinelli, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [20] Isatuximab plus carfilzomib-dexamethasone for relapsed multiple myeloma
    Maruyama, Dai
    Yamauchi, Nobuhiko
    LANCET HAEMATOLOGY, 2024, 11 (10): : e710 - e711
12345